Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment

Reuters

2025/05/22

Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment

ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with Instil Bio, Inc., is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537854917"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537854917\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537854917?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 18:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537854917","market":"us","top_or_hot":-1,"title":"Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with <a href=\"https://laohu8.com/S/TIL\">Instil Bio, Inc.</a>, is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-22 18:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with <a href=\"https://laohu8.com/S/TIL\">Instil Bio, Inc.</a>, is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴資本持倉","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL1NChjy:1","article_id":"2537854917","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537854917","pubTimestamp":1747908578,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmuneOnco Biopharmaceuticals  Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer . The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with Instil Bio, Inc., is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","01541":"宜明昂科-B","BK1161":"生物科技","TIL":"Instil Bio, Inc."},"translate_title":"Immuneonco生物制药宣布IMM2510/AXN-2510一线治疗非小细胞肺癌的新临床试验更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TIL":0.9,"01541":0.9},"content_text":"Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment\n    \n\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with Instil Bio, Inc., is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}